Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) shares fell 0.5% during trading on Monday . The company traded as low as $5.49 and last traded at $5.56, with a volume of 303,272 shares trading hands. The stock had previously closed at $5.59.

A number of research firms recently commented on SPPI. FBR & Co reaffirmed a “buy” rating on shares of Spectrum Pharmaceuticals in a research note on Wednesday, August 10th. Zacks Investment Research raised Spectrum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Tuesday, June 28th. Finally, Jefferies Group reaffirmed a “hold” rating and issued a $6.00 price target (up previously from $5.00) on shares of Spectrum Pharmaceuticals in a research note on Monday, May 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Spectrum Pharmaceuticals presently has an average rating of “Buy” and an average price target of $8.75.

The company has a 50-day moving average of $6.39 and a 200 day moving average of $6.45. The firm’s market capitalization is $377.85 million.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last announced its earnings results on Tuesday, August 9th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.24. The business had revenue of $33.90 million for the quarter, compared to analysts’ expectations of $30.88 million. During the same period in the prior year, the business earned ($0.01) earnings per share. The company’s revenue for the quarter was down 24.6% compared to the same quarter last year. On average, analysts forecast that Spectrum Pharmaceuticals Inc. will post ($1.11) EPS for the current year.

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.